文献速递胸部CT

COVID-19后1年胸部CT肺部异常:系统综述与Meta分析

Chest CT Lung Abnormalities 1 Year after COVID-19: A Systematic Review and Meta-Analysis.
PubMed 文献 · Radiology · 2023-01-01

该系统综述与Meta分析检索2020年1月至2023年1月四个数据库,纳入21项研究进行综述,其中14项研究1854例成人纳入Meta分析,评估COVID-19确诊后1年胸部CT残留肺部异常的患病率及类型。汇总患病率为43.5%(I²=94%;95%预测区间5.9%,90.4%),研究间高度异质,纤维化牵引性支气管扩张/细支气管扩张患病率范围1.6-25.7%,蜂窝影不显著(0-1.1%),肺部后遗症与任何感兴趣特征无关,异质性决定因素仍未知。

要点

  • COVID-19后1年胸部CT残留肺部异常汇总患病率为43.5%(I²=94%;95%预测区间5.9%,90.4%),研究间高度异质。
  • 纤维化牵引性支气管扩张/细支气管扩张患病率范围1.6-25.7%(I²=93%;95%预测区间0.0%,98.6%)。
  • 蜂窝影不显著(0-1.1%;I²=58%;95%预测区间0%,60%),肺部后遗症与任何感兴趣特征无关。

核心结论

  • COVID-19后1年胸部CT肺部后遗症患病率在研究间高度异质,异质性决定因素仍未知,提示数据解读需谨慎,无令人信服的证据。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Web of Science、Embase和Medline数据库2020年1月至2023年1月文献,纳入成人(≥18岁)确诊COVID-19随访1年胸部CT肺部后遗症全文报告;Meta分析纳入胸部CT数据可评估者不少于80%的研究,共14项研究1854/2043例(男/女:1109/934),采用随机效应模型估计汇总患病率,并进行亚组和Meta回归分析。

诊断标准与关键数值

  • 按Fleischner术语表分析任何残留肺部异常及其类型(纤维化或非纤维化)的患病率;汇总患病率43.5%(I²=94%;95%预测区间5.9%,90.4%);纤维化牵引性支气管扩张/细支气管扩张患病率范围1.6-25.7%(I²=93%;95%预测区间0.0%,98.6%);蜂窝影0-1.1%(I²=58%;95%预测区间0%,60%)。

局限性

  • 肺部后遗症估计高度异质(7.1-96.7%)。
  • 异质性决定因素仍未知,提示数据解读需谨慎,无令人信服的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Radiological lung sequelae may explain the persistence of respiratory complaints in post-COVID-19 condition (long-COVID). Purpose To perform a systematic review and meta-analysis of the prevalence and type of COVID-19 residual lung abnormalities at 1-year chest CT. Materials and Methods A literature search of PubMed, Web of Science, Embase, and Medline databases was performed from January 2020 to January 2023. Full-text reports of CT lung sequelae in adults (≥18 years) with confirmed COVID-19 at 1-year follow-up were included. The prevalence of any residual lung abnormality and type (fibrotic or not) was analyzed according to the Fleischner Glossary. The meta-analysis included studies with chest CT data assessable in no less than 80% of individuals. A random-effects model was used to estimate pooled prevalence. Multiple sub-group (country, journal category, methodological quality, study setting, outcomes) and meta-regression analyses were performed to identify potential sources of heterogeneity. I2 statistics estimated low (25%), moderate (26-50%) and high (>50%) heterogeneity. 95% Prediction Intervals (95% PIs) were computed to describe the expected estimates range. Results Of 22 709 records, 21 studies were reviewed (20 prospective, 9 from China, and 7 in radiology journals). The meta-analysis included 14 studies with chest CT data in 1854 of 2043 individuals (M/F: 1109/934). Estimates of lung sequelae were highly heterogeneous (7.1-96.7%), with a pooled frequency of 43.5% (I2=94%; 95% PI: 5.9%, 90.4%). This also applied to single non-fibrotic changes, including ground glass opacity, consolidations, nodules/masses, parenchymal bands, and reticulations. The prevalence range of fibrotic traction bronchiectasis/bronchiolectasis was 1.6-25.7% (I2=93%; 95% PI: 0.0%, 98.6%;); honeycombing was unremarkable (0-1.1%; I2=58%; 95% PI: 0%, 60%). Lung sequelae were unrelated to any characteristics of interest. Conclusion The prevalence of COVID-19 lung sequelae at 1-year chest CT is highly heterogeneous among studies. Heterogeneity determinants remain unknown suggesting caution in data interpretation with no convincing evidence. PROSPERO (CRD42022341258) Keywords: COVID-19 pneumonia, pulmonary fibrosis, chest CT, long-COVID, systematic review, metaanalysis See also the editorial by Parraga and Svenningsen in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Bocchino M, Rea G, Capitelli L, et al. Chest CT Lung Abnormalities 1 Year after COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2023. PMID: 37404150. doi:10.1148/radiol.230535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。